

# WHO Drug Information

## Contents

### Personal Perspectives

- Putting the "partnership" into public-private partnerships 57  
Drug studies in developing countries 58

### Reports on Individual Drugs

- Cannabinoids in the management of pain 60  
Treatment of tuberculosis and standard of care 61

### Vaccines and Biomedicines

- Group procurement of vaccines 62  
The GCC procurement system 63  
Evaluation of candidate HIV vaccines 65  
Diagnosis of prion diseases soon possible? 67

### Current Topics

- Implementation of the ICH common technical document 68  
Monitoring the emergence of antiretroviral resistance 68  
Pharmaceutical legislation review 69  
Argentina takes action against black market 69  
Pharmacopoeial quality of drugs supplied by Nigerian pharmacies 69  
Use of placebo in clinical trials 70  
WHO guidelines on good clinical practice reviewed 71

### General Information

- Harmonization and international drug monitoring 72  
International Federation of Associations of Pharmaceutical Physicians 74

### Regulatory and Safety Matters

- New Zealand and Australia: joint medicines regulatory body 76  
Bupropion safety information 76  
Bupropion update 76  
Itraconazole and congestive heart failure 76  
Terbinafine and hepatic failure 77

- Paediatric amiodarone labelling changes 77  
Cerivastatin: marketing discontinued 77  
Phenylpropanolamine withdrawn from market 78  
Counterfeit filgrastim 78  
Oxycodone: strengthened warning 78  
Nesiritide for heart failure 79  
Oprelvekin: paediatric safety information 79  
Peginterferon alfa-2b combined use: new labelling 79  
Ribavirin for combined use 79  
Sleep attacks with pramipexole and ropinirole 80  
Rosiglitazone associated hepatic and cardiovascular events 80  
Clarithromycin: labelling change 80  
Herbal OTC remedy and hepatic dysfunction 80  
Antipsychotics and high prolactin 81  
Sildenafil: not for use with nitrates 81  
Propofol, heart failure and high dosages 81  
Bupropion and seizures 82  
Neurotoxicity with aciclovir and valaciclovir 82  
Revised labelling for levocarnitine 82  
Avoid trastuzumab and anthracyclines 82

### ATC/DDD Classification

- Final list 84  
Temporary list 86

### Essential Drugs

- Resurgence of sleeping sickness 89

### Recent Publications and Sources of Information

- GMP training modules 91  
Current challenges in pharmacovigilance 91  
WHO Reproductive Health Library 92  
Management of sexually transmitted infections 92  
Safe Blood Starts With Me 92  
Improved access to biomedical journals 92  
Global information flow 93  
First Asian course in problem-based pharmacotherapy teaching 94

### Proposed International

- Nonproprietary Names: List 85 95

Printed in Malta  
2001/13910 - Interprint - 5300